1974 年 24 巻 4 号 p. 551-558
2α, 3α-Epithio-5α-androstan-17β-yl l-methoxycyclopentyl ether (10364-S) was found to possess marked myotropic and androgenic activities by oral route in the rat, and its potency and myotropic-androgenic ratio were estimated to be almost equivalent to those of fluoxymesterone. It was further demonstrated that the oral administration of 10364-S, 20 mg/kg a day for 3 weeks, had hardly no effect on liver function of rabbits tested by BSP retention, plasma GOT and GPT activities, and plasma cholesterol levels, whereas treatment with methyltestosterone, oxymetholone or fluoxymesterone, at the same dosage, caused abnormal BSP retention and plasma GOT activity. It is thus concluded, that 10364-S when given orally is an active anabolic agent with a therapeutic potency equivalent to fluoxymesterone yet in clinical administration is less likely to cause hepatic disturbance.
